Open Orphan PLC - pharmaceutical services provider - Says its subsidiary Venn Life Sciences has been awarded a contract for a study with Oxford BioTherapeutics, a clinical stage oncology company. The agreement is for a phase I, open-label, dose finding study which will be used to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in solid tumours and in women with breast cancer. The study is due to start immediately, the company notes. No financial details were disclosed.
Current stock price: 28.63 pence, down 1.3% on Tuesday
Year-to-date change: up 11%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.